Eli L Diamond

List of Publications by Year
in descending order

78 papers	6,784 citations	136950 32 h-index	76900 74 g-index
81 all docs	81 docs citations	81 times ranked	7524 citing authors

#	Article	IF	Citations
1	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. New England Journal of Medicine, 2015, 373, 726-736.	27.0	1,483
2	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 2016, 127, 2672-2681.	1.4	1,040
3	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood, 2014, 124, 483-492.	1.4	462
4	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
5	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood, 2018, 131, 2877-2890.	1.4	335
6	Vemurafenib for BRAF V600â€“Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. JAMA Oncology, 2018, 4, 384.	7.1	280
7	Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature, 2019, 567, 521-524.	27.8	222
8	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood, 2014, 124, 3016-3019.	1.4	197
9	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood, 2020, 135, 1929-1945.	1.4	191
10	Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood, 2017, 130, 167-175.	1.4	136
11	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	30.7	122
12	Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71.	9.4	115
13	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	7.0	107
14	The histopathology of Erdheimâ€“Chester disease: a comprehensive review of a molecularly characterized cohort. Modern Pathology, 2018, 31, 581-597.	5.5	102
15	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood, 2017, 130, 176-180.	1.4	98
16	High prevalence of myeloid neoplasms in adults with nonâ€“Langerhans cell histiocytosis. Blood, 2017, 130, 1007-1013.	1.4	98
17	Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	9.4	93
18	Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true â€œoligoastrocytomaâ€?. Acta Neuropathologica, 2015, 129, 151-153.	7.7	87

#	Article	IF	Citations
19	Rates and risks for late referral to hospice in patients with primary malignant brain tumors. Neuro-Oncology, 2016, 18, 78-86.	1.2	69
20	International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood, 2022, 139, 2601-2621.	1.4	63
21	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget, 2016, 7, 85430-85436.	1.8	60
22	ALK-positiveÂhistiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood, 2022, 139, 256-280.	1.4	60
23	Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatric Blood and Cancer, 2018, 65, e26784.	1.5	59
24	Detection of an NRAS mutation in Erdheim-Chester disease. Blood, 2013, 122, 1089-1091.	1.4	57
25	Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma. Neuro-Oncology, 2017, 19, 1532-1541.	1.2	51
26	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. Journal of Clinical Investigation, 2018, 128, 3819-3825.	8.2	45
27	Existential distress among caregivers of patients with brain tumors: a review of the literature. Neuro-Oncology Practice, 2016, 3, 232-244.	1.6	44
28	Frequency and Risk Factors for Live Discharge from Hospice. Journal of the American Geriatrics Society, 2017, 65, 1726-1732.	2.6	42
29	Prognostic awareness and communication of prognostic information in malignant glioma: a systematic review. Journal of Neuro-Oncology, 2014, 119, 227-234.	2.9	41
30	Single-agent dabrafenib for BRAF ^{V600E} -mutated histiocytosis. Haematologica, 2018, 103, e177-e180.	3.5	40
31	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of Clinical Oncology, 2018, 36, 1702-1709.	1.6	39
32	Histiocytic neoplasms in the era of personalized genomic medicine. Current Opinion in Hematology, 2016, 23, 416-425.	2.5	37
33	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica, 2020, 105, e5-e8.	3.5	34
34	The coming of age of Langerhans cell histiocytosis. Nature Immunology, 2020, 21, 1-7.	14.5	34
35	Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro-Oncology, 2021, 23, 1433-1446.	1.2	33
36	Neurologic and oncologic features of Erdheimâ€“Chester disease: a 30-patient series. Neuro-Oncology, 2020, 22, 979-992.	1.2	31

#	Article	IF	Citations
37	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics, 2019, 18, 1149-1157.	4.1	26
38	Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1277-1303.	4.9	26
39	Dynamic Contrastâ€Enhanced MRI in Lowâ€Grade Versus Anaplastic Oligodendrogliomas. Journal of Neuroimaging, 2016, 26, 366-371.	2.0	25
40	Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood, 2016, 128, 1896-1898.	1.4	24
41	Minor Cognitive Impairments in Cancer Patients Magnify the Effect of Caregiver Preferences on End-of-Life Care. Journal of Pain and Symptom Management, 2013, 45, 650-659.	1.2	23
42	Rosai-Dorfman Diseaseâ€"Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. Clinical Nuclear Medicine, 2020, 45, e260-e266.	1.3	22
43	Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma. Journal of Pain and Symptom Management, 2017, 53, 257-264.	1.2	20
44	Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet Journal of Rare Diseases, 2016, 11, 109.	2.7	19
45	Nonenhancing Leptomeningeal Metastases. Neurohospitalist, The, 2016, 6, 24-28.	0.8	19
46	Palliative Care in High-Grade Glioma: A Review. Brain Sciences, 2020, 10, 723.	2.3	18
47	A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood Advances, 2019, 3, 934-938.	5.2	17
48	Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2018, 65, e26699.	1.5	16
49	Erdheim-Chester disease: the â€œtargetedâ€•revolution. Blood, 2017, 130, 1282-1284.	1.4	12
50	Giant cell arteritis presenting with bilateral orbital inflammatory disease and enhancing superficial temporal arteries. Practical Neurology, 2014, 14, 446-447.	1.1	11
51	18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1154-1165.	6.4	10
52	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. Blood, 2018, 132, 49-49.	1.4	10
53	MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. Ocular Oncology and Pathology, 2020, 6, 159-163.	1.0	8
54	The unique burden of rare cancer caregiving: caregivers of patients with Erdheimâ€"Chester disease. Leukemia and Lymphoma, 2020, 61, 1406-1417.	1.3	8

#	Article	IF	Citations
55	High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system. Leukemia and Lymphoma, 2016, 57, 1961-1964.	1.3	7
56	Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheimâ€“Chester disease patients following BRAF inhibitor monotherapy. Neuro-Oncology Advances, 2020, 2, vdaa024.	0.7	7
57	Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study. Neuro-Oncology Advances, 2021, 3, vdaa159.	0.7	7
58	Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists. Journal of Neuro-Oncology, 2022, 158, 69-79.	2.9	7
59	Cobimetinibâ€induced â€œdropped head syndromeâ€•and subsequent disease management in an Erdheimâ€Chester patient. Clinical Case Reports (discontinued), 2019, 7, 1989-1993.	0.5	6
60	Rosaiâ€“Dorfmanâ€“Destombes disease of the nervous system: a systematic literature review. Orphanet Journal of Rare Diseases, 2022, 17, 92.	2.7	6
61	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro-Oncology, 2023, 25, 199-210.	1.2	6
62	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheimâ€“Chester Disease. Cancers, 2020, 12, 3240.	3.7	5
63	Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. Ophthalmology Retina, 2021, 5, 1187-1195.	2.4	5
64	Visualization of Orbital Involvement of Erdheim-Chester Disease on PET/CT. Clinical Nuclear Medicine, 2014, 39, 660-661.	1.3	4
65	A Population-Based Study of Treatment and Survival in Older Glioma Patients. JNCI Cancer Spectrum, 0, , .	2.9	4
66	Transient aqueductal occlusion in intracerebral haemorrhage. Practical Neurology, 2012, 12, 388-389.	1.1	3
67	Associations between Mild Cognitive Dysfunction and End-of-Life Outcomes in Patients with Advanced Cancer. Journal of Palliative Medicine, 2018, 21, 536-540.	1.1	3
68	Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. Neurology, 2021, 96, 1091-1093.	1.1	3
69	MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia, 2021, , .	7.2	3
70	Progressive nodular histiocytosis in a 9â€yearâ€old boy treated with cobimetinib. Pediatric Dermatology, 2022, 39, 115-118.	0.9	3
71	Erdheim-Chester Disease. , 2018, , 313-338.		2
72	Letter to the Editor Regarding â€œNational Trends for Reoperation in Older Patients with Glioblastomaâ€• World Neurosurgery, 2018, 117, 466.	1.3	2

#	Article	IF	Citations
73	Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment. American Journal of Ophthalmology Case Reports, 2020, 20, 100868.	0.7	2
74	Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e686.	6.0	2
75	Ethics consultations in neuro-oncology. Neuro-Oncology Practice, 2021, 8, 539-549.	1.6	2
76	The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease. Blood, 2018, 132, 2397-2397.	1.4	1
77	Temporal Lobe Meningioma With Ipsilateral Herpes Simplex Encephalitis. Neurohospitalist, The, 2014, 4, 42-43.	0.8	0
78	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. Blood, 2017, 130, 794-794.	1.4	0